Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

beta2-microglobulin-derived amyloidosis: an update.

J Floege1, M Ketteler

  • 1Division of Nephrology, University of Aachen, Aachen, Germany. juergen.Floege@post.rwth-aachen.de

Kidney International. Supplement
|February 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Time-dependent lipid profile inversely associates with mortality in hemodialysis patients - independent of inflammation/malnutrition.

Journal of internal medicine·2021
Same author

Management of primary and renal hyperparathyroidism: guidelines from the German Association of Endocrine Surgeons (CAEK).

Langenbeck's archives of surgery·2021
Same author

Heart failure in advanced chronic kidney disease: treatment rationale.

Herz·2021
Same author

[Immunoglobulin A nephropathy].

Der Internist·2019
Same author

[What is certain in the treatment of glomerulonephritis?]

Der Internist·2018
Same author

[Choosing wisely recommendations in nephrology].

Der Internist·2017
Same journal

Effect of kidney disease on glucose handling (including genetic defects).

Kidney international. Supplement·2011
Same journal

Need for better diabetes treatment for improved renal outcome.

Kidney international. Supplement·2011
Same journal

Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans.

Kidney international. Supplement·2011
Same journal

SGLT2 inhibitors: molecular design and potential differences in effect.

Kidney international. Supplement·2011
Same journal

Glucose handling by the kidney.

Kidney international. Supplement·2011
Same journal

Bone: from a reservoir of minerals to a regulator of energy metabolism.

Kidney international. Supplement·2011
See all related articles

Beta2-microglobulin-derived amyloidosis (Aβ2m amyloidosis) in dialysis patients stems from retained beta2-microglobulin (β2m). Recent advancements focus on prevention strategies and improved diagnostics for this condition.

Area of Science:

  • Nephrology
  • Biochemistry
  • Pathology

Background:

  • Beta2-microglobulin (β2m) accumulation in chronic kidney disease patients undergoing dialysis is a key factor in Aβ2m amyloidosis.
  • Secondary molecular modifications, including proteolysis and glycation, contribute to β2m amyloid formation.
  • Local factors in synovial membranes may predispose to amyloid deposition in joints.

Purpose of the Study:

  • To review recent developments in beta2-microglobulin-derived amyloidosis (Aβ2m amyloidosis) in patients on chronic dialysis.
  • To summarize advances in understanding pathogenesis, diagnosis, and prevention of Aβ2m amyloidosis.

Main Methods:

  • Review of recent literature on Aβ2m amyloidosis.
  • Analysis of factors contributing to disease pathogenesis, clinical presentation, and diagnosis.

Related Experiment Videos

  • Evaluation of preventive strategies in dialysis therapy.

    • Main Results:

    • Clinically apparent Aβ2m amyloidosis is less widespread than histological findings suggest.
    • Technical improvements in β2m scintigraphy enhance noninvasive diagnosis.
    • High-flux dialysis membranes, dialysate quality, and composition are crucial for Aβ2m amyloidosis prevention.

    Conclusions:

    • Aβ2m amyloidosis pathogenesis involves β2m retention, molecular modifications, and local factors.
    • Early diagnosis and prevention strategies are critical for managing Aβ2m amyloidosis in dialysis patients.
    • Improvements in dialysis technology and care may be reducing the prevalence of Aβ2m amyloidosis.